IP Library Granted Patent US 9,907,786
Granted Patent B2
US 9,907,786 · App. 15/337,987 · Granted Mar 6, 2018

Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof

Inventors: Gene H. Zaid (Sterling, KS); Thomas W. Burgoyne (Sterling, KS)
Assignee: Ions Pharmaceutical S.à r.l.
A61K31/437A61K31/11A61K31/12A61K31/4375A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,786
App. No.
15/337,987
Granted
Mar 6, 2018
Kind
B2
Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Claims (10)

1. An anti-cancer composition of matter comprising harmaline and a compound of the structure

where Q9 is a C3 aldehyde, and Q10 and Q11 are both H, the ratio of said harmaline to said compound being from about 0.5:1 to 15:1, said compound being present at a level of from about 25-95% by weight, and said harmaline being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

2. The composition of claim 1 , said composition consisting essentially of harmaline and said compound.

3. The composition of claim 1 , wherein said harmaline and said compound of the structure

where Q9 is a C3 aldehyde, and Q10 and Q11 are both H is in the form of an ester, metal complex, or pharmaceutically acceptable salt.

4. A method of preparing an anti-cancer composition comprising the step of mixing together harmaline and a compound of the structure

where Q9 is a C3 aldehyde, and Q10 and Q11 are both H, the ratio of said harmaline to said compound being from about 0.5:1 to 15:1, said compound being present at a level of from about 25-95% by weight, and said harmaline being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

5. The method of claim 4 , including the step of mixing said harmaline and said compound of the structure

where Q9 is a C3 aldehyde, and Q10 and Q11 are both H in ethanol, and sonicating the mixture.

6. A product prepared by the method of claim 4 .

Assignments (3)
MERGER Recorded Aug 30, 2018
From: IONS PHARMACEUTICAL S.A R.L.
To: ANKH LIFE SCIENCES LIMITED
Reel/Frame 046760/0741 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD CONVEYING DATA PREVIOUSLY RECORDED AT REEL: 040173 FRAME: 0967. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 3, 2016
From: ZAID, GENE H.; BURGOYNE, THOMAS W.; GENZADA PHARMACEUTICALS LLC
To: IONS PHARMACEUTICAL S.À R.L.
Reel/Frame 040561/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2016
From: ZAID, GENE H.; BURGOYNE, THOMAS W.; GENZADA PHARMACEUTIALS LLC
To: IONS PHARMACEUTICAL S.À R.L.
Reel/Frame 040173/0967 →
Continuity (8)
Continuation PCTUS2015055968 · Oct 16, 2015
Continuation In Part 14721011 · May 26, 2015
Continuation PCTIB2016000723 · Apr 20, 2016
Continuation In Part 14721011
Provisional Application 62184051 · Jun 24, 2015
Provisional Application 62161090 · May 13, 2015
Provisional Application 62066686 · Oct 21, 2014
Related Publication 20170042866A1 · Feb 16, 2017